Antiarrhythmic Drugs—Clinical Use and Clinical Decision Making: A Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology | Heart Rhythm Society

Antiarrhythmic Drugs—Clinical Use and Clinical Decision Making: A Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology

The Heart Rhythm Society affirmed the value of the document on August 24, 2017.

February 9, 2018—The European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology convened a Task Force, with representation from the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS), with the remit to comprehensively review the available evidence to publish a joint practical guide on antiarrhythmic drug therapy and to provide up-to-date consensus recommendations for decision making and its use in everyday clinical practice. The ultimate judgement regarding the care of a particular patient must be made by the health care provider and the patient in light of all of the circumstances presented by that patient.

HRS Endorsed / Affirmed
Atrial Arrhythmias
Atrial Fibrillation

The consensus statement's objective is not to offer a new pharmacology textbook or a research perspectives review but to provide a practical document intended for general cardiologists, internal medicine specialists, general practitioners, and cardiology fellows or residents based on the current knowledge and clear recommendations.